ES2900825T3 - Método de tratamiento adyuvante para el cáncer - Google Patents

Método de tratamiento adyuvante para el cáncer Download PDF

Info

Publication number
ES2900825T3
ES2900825T3 ES13835019T ES13835019T ES2900825T3 ES 2900825 T3 ES2900825 T3 ES 2900825T3 ES 13835019 T ES13835019 T ES 13835019T ES 13835019 T ES13835019 T ES 13835019T ES 2900825 T3 ES2900825 T3 ES 2900825T3
Authority
ES
Spain
Prior art keywords
melanoma
dabrafenib
trametinib
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13835019T
Other languages
English (en)
Spanish (es)
Inventor
Sylvie Laquerre
Peter F Lebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2900825(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2900825T3 publication Critical patent/ES2900825T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES13835019T 2012-09-04 2013-08-30 Método de tratamiento adyuvante para el cáncer Active ES2900825T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
ES2900825T3 true ES2900825T3 (es) 2022-03-18

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13835019T Active ES2900825T3 (es) 2012-09-04 2013-08-30 Método de tratamiento adyuvante para el cáncer

Country Status (20)

Country Link
US (7) US20150216868A1 (enExample)
EP (2) EP2892535B1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
CN111534580B (zh) 2013-12-28 2024-06-04 夸登特健康公司 用于检测遗传变异的方法和系统
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法

Also Published As

Publication number Publication date
PL2892535T3 (pl) 2022-01-31
JP2015527374A (ja) 2015-09-17
CA2882437A1 (en) 2014-03-13
US20180338979A1 (en) 2018-11-29
JP6684941B2 (ja) 2020-04-22
IN2015KN00449A (enExample) 2015-07-17
CA2882437C (en) 2021-03-02
US20200054641A1 (en) 2020-02-20
EP2892535A1 (en) 2015-07-15
PT2892535T (pt) 2021-12-15
JP6511117B2 (ja) 2019-05-15
US20170202842A1 (en) 2017-07-20
JP2019142899A (ja) 2019-08-29
AU2016244279B2 (en) 2018-01-04
HK1206642A1 (en) 2016-01-15
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
BR112015004578A2 (pt) 2017-07-04
US20210060021A1 (en) 2021-03-04
CY1124812T1 (el) 2022-11-25
US20260207608A1 (en) 2026-07-23
EP2892535B1 (en) 2021-09-22
WO2014039375A1 (en) 2014-03-13
RU2640180C2 (ru) 2017-12-26
HRP20211817T1 (hr) 2022-03-04
US20150216868A1 (en) 2015-08-06
EP2892535A4 (en) 2016-04-13
AU2013313050A1 (en) 2015-03-26
DK2892535T3 (da) 2022-01-03
HUE056646T2 (hu) 2022-02-28
KR20150047619A (ko) 2015-05-04
KR102134585B1 (ko) 2020-07-17
SI2892535T1 (sl) 2022-01-31
CN107308164A (zh) 2017-11-03
CN104582706A (zh) 2015-04-29
JP2018058859A (ja) 2018-04-12
US20230330091A1 (en) 2023-10-19
AU2016244279A1 (en) 2016-11-03
EP3981408A1 (en) 2022-04-13
US10869869B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
US10869869B2 (en) Method of adjuvant cancer treatment
US10849899B2 (en) Combination therapy comprising Varlitinib and an anticancer agent
ES3064856T3 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
ES2793286T3 (es) Derivado de quinolina contra carcinoma de pulmón no microcítico
ES2899636T3 (es) Tinostamustina para su uso en el tratamiento de cáncer de ovario
ES2959952T3 (es) Compuestos para el tratamiento del CMTN
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
EP3443962A1 (en) Quinoline derivative for treating gastric cancer
TWI891650B (zh) 治療血管畸形之方法
TW201600086A (zh) 用於治療三陰性乳癌之維利帕尼（ｖｅｌｉｐａｒｉｂ）與卡鉑之組合
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
AU2017288094A1 (en) Maintenance therapy for the treatment of cancer
HK1206642B (en) Method of adjuvant cancer treatment
CN107921039A (zh) 用于胆道癌的治疗剂